CORRECTED: Rival Drug Didn't Infringe Genzyme's Arthritis Patent: Jury

Law360, New York (August 6, 2012, 5:43 PM EDT) -- A federal jury in Massachusetts found Friday that drugmakers Seikagaku Corp. and Zimmer Inc. hadn't infringed Genzyme Corp.'s patent for osteoarthritis knee pain treatment Synvisc-One by marketing a rival pain treatment.

The jurors said Seikagaku's recently approved Gel-One product — distributed in the U.S. by Zimmer — didn't infringe Genzyme's patent. The jury also said that several of the patent's claims were invalid due to obviousness.

The decision marks a sharp reversal for Genzyme, coming after the Sanofi SA subsidiary secured a preliminary injunction on sales...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.